Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial

Pradeesh Sivapalan, Charlotte Suppli Ulrik, Therese Sophie Lapperre, Rasmus Dahlin Bojesen, Josefin Eklöf, Andrea Browatzki, Jon Torgny Wilcke, Vibeke Gottlieb, Kjell Erik Julius Håkansson, Casper Tidemandsen, Oliver Tupper, Howraman Meteran, Christina Bergsøe, Eva Brøndum, Uffe Bødtger, Daniel Bech Rasmussen, Sidse Graff Jensen, Lars Pedersen, Alexander Jordan, Helene Priemé, Christian Søborg, Ida E. Steffensen, Dorthe Høgsberg, Tobias Wirenfeldt Klausen, Martin Steen Frydland, Peter Lange, Asger Sverrild, Muhzda Ghanizada, Filip K. Knop, Tor Biering-Sørensen, Jens D. Lundgren, Jens-Ulrik Stæhr Jensen

Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021
Journal Issue: January

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Pradeesh Sivapalan, Charlotte Suppli Ulrik, Therese Sophie Lapperre, Rasmus Dahlin Bojesen, Josefin Eklöf, Andrea Browatzki, Jon Torgny Wilcke, Vibeke Gottlieb, Kjell Erik Julius Håkansson, Casper Tidemandsen, Oliver Tupper, Howraman Meteran, Christina Bergsøe, Eva Brøndum, Uffe Bødtger, Daniel Bech Rasmussen, Sidse Graff Jensen, Lars Pedersen, Alexander Jordan, Helene Priemé, Christian Søborg, Ida E. Steffensen, Dorthe Høgsberg, Tobias Wirenfeldt Klausen, Martin Steen Frydland, Peter Lange, Asger Sverrild, Muhzda Ghanizada, Filip K. Knop, Tor Biering-Sørensen, Jens D. Lundgren, Jens-Ulrik Stæhr Jensen. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021
Year: 2022



Azithromycin and Hydroxychloroquine in hospitalized patients with confirmed SARS-CoV-2 infection - a randomized placebo-controlled trial (ProPAC-COVID Trial)
Source: Virtual Congress 2021 – COVID - 19 treatments
Year: 2021


Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial
Source: International Congress 2019 – Airway infection in COPD
Year: 2019

Randomized double-blind placebo-controlled trial of azithromycin in lung transplantation: first results
Source: Annual Congress 2008 - New insights and treatment options for bronchiolitis obliterans syndrome after lung transplantation
Year: 2008


Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Towards controlling severe asthma
Year: 2007


A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis
Source: Eur Respir J 2014; 43: 1114-1123
Year: 2014



Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

Umeclidinium in patients with COPD: a randomised, placebo-controlled study
Source: Eur Respir J 2014; 43: 72-81
Year: 2004



Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD
Source: Annual Congress 2009 - Healthcare and treatment of COPD
Year: 2009


A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008


The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial
Source: Eur Respir J, 58 (4) 2002819; 10.1183/13993003.02819-2020
Year: 2021



Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
Source: Eur Respir J, 59 (2) 2101471; 10.1183/13993003.01471-2021
Year: 2022



PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017



Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008


Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial
Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021
Year: 2021



A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018

Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial
Source: Eur Respir J 2002; 20: Suppl. 38, 146s
Year: 2002

Sedation for bronchoscopy in children: a prospective randomized double-blinded trial
Source: Virtual Congress 2021 – Posters in paediatric bronchology
Year: 2021


Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017